The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis

Liver International

Volumn 36, Issue 12, 2016, Pages 1860-1866

  Ferraioli, Giovanna ^a   Tinelli, Carmine ^b   De Silvestri, Annalisa ^b   Lissandrin, Raffaella ^a   Above, Elisabetta ^a   Dellafiore, Carolina ^a   Poma, Gianluigi ^a   Di Gregorio, Marta ^a   Maiocchi, Laura ^a   Maserati, Renato ^a   Filice, Carlo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

controlled attenuation parameter; liver steatosis; transient elastography; ultrasound

Indexed keywords

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FATTY LIVER; FEMALE; GOLD STANDARD; HEPATITIS VIRUS; HUMAN; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METHODOLOGY; MIDDLE AGED; NON INVASIVE PROCEDURE; PREVALENCE; ULTRASOUND SCANNER; AGED; AREA UNDER THE CURVE; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; ELASTOGRAPHY; ITALY; LIVER; LIVER CIRRHOSIS; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AREA UNDER CURVE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HUMANS; ITALY; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84994385655     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13207     Document Type: Article

References (30)

1. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.
2. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75–85.
3. Kurosaki M, Hosokawa T, Matsunaga K, et al. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res. 2010;40:870–877.
4. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–2715.
5. Perez NE, Siddiqui FA, Mutchnick MG, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol. 2007;41:624–629.
6. Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol. 2005;5:14.
7. Lee SS, Park SH, Kim HJ, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52:579–585.
8. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.
9. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918.
10. ®: validation in chronic hepatitis C. J Viral Hepat. 2012;19:244–253.
11. Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.
12. Kumar M, Rastogi A, Singh T, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol. 2013;28:1194–1201.
13. Ferraioli G, Tinelli C, Lissandrin R, et al. Controlled attenuation parameter for evaluation of liver steatosis in chronic viral hepatitis. World J Gastroenterol. 2014;20:6626–6631.
14. Chon YE, Jung KS, Kim SU, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014;34:102–109.
15. de Lédinghen VD, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5,323 examinations. J Hepatol. 2014;60:1026–1031.
16. Shi KQ, Tang JZ, Zhu XL, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149–1158.
17. Carvalhana S, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver Int. 2014;34:e111–e117.
18. Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–1191.
19. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–659.
20. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess. 2007;11: iii, ix–51.
21. Hawkins DM, Garrett JA, Stephenson B. Some issues in resolution of diagnostic tests using an imperfect gold standard. Stat Med. 2001;20:1987–2001.
22. Poynard T, Ingiliz P, Elkrief L, et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One. 2008;3:e3857.
23. Lim C, Wannapinij P, White L, et al. Using a web-based application to define the accuracy of diagnostic tests when the gold standard is imperfect. PLoS One. 2013;8:e79489.
24. Peng CJ, Yuan D, Li B, et al. Body mass index evaluating donor hepatic steatosis in living donor liver transplantation. Transplant Proc. 2009;41:3556–3559.
25. Rinella ME, Alonso E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001;7:409–414.
26. Sasso M, Audière S, Kemgang A, et al. Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy. Ultrasound Med Biol. 2016;42:92–103.
27. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061–1067.
28. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.
29. EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.
30. Collins J, Huynh M. Estimation of diagnostic test accuracy without full verification: a review of latent class methods. Stat Med. 2014;33:4141–4169.